An Open Label, Single Dose Escalation Study Of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Jul 2010
At a glance
- Drugs Ponezumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Pfizer
- 07 Jun 2017 Biomarkers information updated
- 10 Jul 2010 Results presented at the International Conference on Alzheimer's Disease and Related Disorders in July 2010
- 05 Sep 2008 New trial record.